Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Darinaparsin · 2 trials · 4 indications
a primary outcome measure is to determine the toxicity profile of oral darinaparsin when given continuously for 21 days followed by a 7 day rest period per cycle
a primary outcome measure is to determine the maximum tolerated dose of oral darinaparsin when given continuously for 21 days followed by a 7 day rest period per cycle
a primary outcome measure is to determine the preliminary activity/efficacy of oral darinaparsin when given continuously for 21 days followed by a 7 day rest period per cycle
a primary outcome measure is to determine the pharmacokinetic profile of oral darinaparsin when given continuously for 21 days followed by a 7 day rest period per cycle
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | - |
| oral darinaparsin | EXPERIMENTAL | open label, single arm, dose escalation |
| Name | Type | Description |
|---|---|---|
| Darinaparsin | DRUG | 300mg/m2 of Darinaparsin given daily for five consecutive days to be repeated every 28 days for up to six months. |
Inclusion Criteria 1. Hodgkin's or non-Hodgkin's Lymphoma. 2. ≥ 1 prior therapy and currently requiring therapy. 3. Evaluable disease (defined by disease-specific criteria listed in Appendix 1) 4. ≥ 18 years of age. 5. ECOG performance score ≤ 2 (see Appendix 2). 6. Life-expectancy ≥ 2 months. 7. W...
Darinaparsin is an investigational small molecule being studied for the treatment of hematologic neoplasms and advanced solid tumors. It is in Phase 2 clinical development for these oncology indications. The drug is not FDA approved and remains under clinical investigation.
Darinaparsin is being developed by Alaunos Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol TCRT. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with certain blood cancers and advanced solid tumors.
Darinaparsin is in Phase 2 clinical development for hematologic neoplasms and advanced solid tumors. It is an investigational drug, meaning it has not been approved by the FDA and is still undergoing clinical trials to assess its safety and effectiveness in treating these conditions.
Darinaparsin has been studied in two completed clinical trials. NCT00421213 was a Phase 2 study of ZIO-101 in advanced blood and bone marrow cancers with 50 participants. NCT01139346 was a Phase 1 study of oral Darinaparsin in patients with advanced solid tumors with 12 participants. Both trials were conducted in the United States.
Yes, Darinaparsin is also known as ZIO-101. The Phase 2 clinical trial NCT00421213, which studied the drug in advanced blood and bone marrow cancers, refers to it as ZIO-101. This alternative name is used in some clinical research contexts.